|Articles|February 1, 2002

Optimal Cholesterol Management: New Strategies
Volume 8
Issue 2 Suppl

Rising to the Challenge of the New NCEP ATP III Guidelines: Exceeding Current Therapeutic Limitations

Author(s)H. Bryan Brewer, JR, MD

Download PDF: Rising to the Challenge of the New NCEP ATP III Guidelines: Exceeding Current Therapeutic Limitations

Articles in this issue

over 24 years ago

Article

Participating Faculty

over 24 years ago

Article

Introduction

over 24 years ago

Article

State of the Art in Cholesterol Management: Targeting Multiple Pathways

over 24 years ago

Article

Preclinical and Clinical Pharmacology of a New Class of Lipid Management Agents

over 24 years ago

Article

An Investigative Look: Selective Cholesterol Absorption Inhibitors - Embarking on a New Standard of Care

over 24 years ago

Article

Future Outlook: Changing Perspectives on Best Practice

over 24 years ago

Article

Panel Discussion

over 24 years ago

Article

Continuing Medical Education Quiz

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Rising to the Challenge of the New NCEP ATP III Guidelines: Exceeding Current Therapeutic Limitations

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access